Aligos Therapeutics, Inc. (ALGS)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Lawrence M. Blatt
Employees:
90
ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO, CA 94080
(800) 466-6059

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB)

Data derived from most recent annual or quarterly report
Market Cap 48.952 Million Shares Outstanding42.94 Million Avg 30-day Volume 393.351 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.44
Price to Revenue2.6944 Debt to Equity0.0 EBITDA-82.84 Million
Price to Book Value0.4425 Operating Margin-617.4366 Enterprise Value-66.41 Million
Current Ratio3.897 EPS Growth0.416 Quick Ratio3.687
1 Yr BETA 0.8846 52-week High/Low 2.41 / 0.84 Profit Margin-599.0804
Operating Cash Flow Growth23.4788 Altman Z-Score-5.6589 Free Cash Flow to Firm -72.66 Million
Earnings Report2023-08-03
View SEC Filings from ALGS instead.

View recent insider trading info

Aligos Therapeutics, Inc. YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding ALGS (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ALGS

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-03-17 by MCCLURE MATTHEW W.
  • 4: filed on 2023-03-17 by QUAN LUCINDA Y.
  • 4: filed on 2023-03-17 by BLATT LAWRENCE
  • 4: filed on 2022-07-11 by MCCLURE MATTHEW W.
  • 4: filed on 2022-07-11 by QUAN LUCINDA Y.
  • 4: filed on 2022-07-11 by CALHOUN LESLEY ANN
  • 4: filed on 2022-07-11 by BEIGELMAN LEONID
  • 4: filed on 2022-07-11 by BLATT LAWRENCE
  • 4: filed on 2022-07-11 by SYMONS JULIAN A.
  • 4: filed on 2022-06-27 by WOIWODE THOMAS

    • Events (8k)

  • 8-K: filed on 2023-05-04:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-02:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-04:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-27:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2022-05-04:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-30:
    Item 8.01: Other Events
  • 8-K: filed on 2022-03-22:
    Item 8.01: Other Events
  • 8-K: filed on 2022-03-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-01-06:
    Item 8.01: Other Events

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    BLATT LAWRENCE CHIEF EXECUTIVE OFFICER

    • Officer
    		 1,704,572 2023-03-15 2

    CALHOUN LESLEY ANN

    • SEE REMARKS
    		 0 2023-03-15 2

    QUAN LUCINDA Y. SEE REMARKS

    • Officer
    		 384,805 2023-03-15 2

    BEIGELMAN LEONID PRESIDENT

    • Officer
    • Director
    		 1,844,619 2023-03-15 2

    SYMONS JULIAN A. SEE REMARKS

    • Officer
    		 394,064 2023-03-15 2

    MCCLURE MATTHEW W. CHIEF MEDICAL OFFICER

    • Officer
    		 91,204 2023-03-15 2

    SCOPA JAMES PAUL

    • Director
    		 15,000 2022-06-23 1

    NIELSEN JACK

    • Director
    		 15,000 2022-06-23 1

    WOIWODE THOMAS

    • Director
    		 15,000 2022-06-23 1

    MARTELL BRIDGET A

    • Director
    		 15,000 2022-06-23 1

    NUECHTERLEIN CAROLE

    • Director
    		 15,000 2022-06-23 1

    HIRTH PETER

    • Director
    		 15,000 2022-06-23 1

    NOVO HOLDINGS A/S

    • 10% Owner
    		 No longer subject to file 2020-10-20 0

    VIVO CAPITAL VIII, LLC

    VIVO CAPITAL FUND VIII, L.P.

    VIVO CAPITAL SURPLUS FUND VIII, L.P.

    • 10% Owner
    		 6,544,060 2020-10-20 0

    VERSANT VENTURE CAPITAL VI, L.P.

    VERSANT VANTAGE I, L.P.

    • 10% Owner
    		 No longer subject to file 2020-10-20 0

    WELLINGTON BIOMEDICAL INNOVATION MASTER INVESTORS (CAYMAN) I L.P.

    • 10% Owner
    		 No longer subject to file 2020-10-20 0

    GLAUB KATHLEEN SEREDA

    • Director
    		 59,550 2020-10-15 0

    MOLDT PETER

    • Director
    		 0 2020-10-15 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    ALIGOS THERAPEUTICS INC ALGS 2023-05-31 22:15:04 UTC -18.9088 23.9688 250000
    ALIGOS THERAPEUTICS INC ALGS 2023-05-31 21:45:04 UTC -18.9088 23.9688 250000
    ALIGOS THERAPEUTICS INC ALGS 2023-05-31 21:15:03 UTC -18.9088 23.9688 250000
    ALIGOS THERAPEUTICS INC ALGS 2023-05-31 20:45:04 UTC -18.9088 23.9688 250000
    ALIGOS THERAPEUTICS INC ALGS 2023-05-31 20:15:06 UTC -18.9088 23.9688 250000
    ALIGOS THERAPEUTICS INC ALGS 2023-05-31 19:45:04 UTC -18.9088 23.9688 250000
    ALIGOS THERAPEUTICS INC ALGS 2023-05-31 19:15:21 UTC -18.9088 23.9688 250000
    ALIGOS THERAPEUTICS INC ALGS 2023-05-31 18:45:03 UTC -18.9088 23.9688 250000
    ALIGOS THERAPEUTICS INC ALGS 2023-05-31 18:15:04 UTC -18.9088 23.9688 250000
    ALIGOS THERAPEUTICS INC ALGS 2023-05-31 17:45:03 UTC -18.9088 23.9688 250000
    ALIGOS THERAPEUTICS INC ALGS 2023-05-31 17:15:05 UTC -18.9088 23.9688 250000
    ALIGOS THERAPEUTICS INC ALGS 2023-05-31 16:45:04 UTC -19.0749 24.1449 250000
    ALIGOS THERAPEUTICS INC ALGS 2023-05-31 16:15:04 UTC -19.0749 24.1449 250000
    ALIGOS THERAPEUTICS INC ALGS 2023-05-31 15:45:03 UTC -19.0749 24.1449 250000
    ALIGOS THERAPEUTICS INC ALGS 2023-05-31 15:15:04 UTC -19.0749 24.1449 250000
    ALIGOS THERAPEUTICS INC ALGS 2023-05-31 14:45:04 UTC -19.0749 24.1449 250000
    ALIGOS THERAPEUTICS INC ALGS 2023-05-31 14:15:03 UTC -19.0749 24.1449 200000
    ALIGOS THERAPEUTICS INC ALGS 2023-05-31 13:45:04 UTC -18.4485 23.5185 200000
    ALIGOS THERAPEUTICS INC ALGS 2023-05-31 13:15:04 UTC -18.4485 23.5185 200000
    ALIGOS THERAPEUTICS INC ALGS 2023-05-31 12:45:04 UTC -18.4485 23.5185 200000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments